191 related articles for article (PubMed ID: 26212543)
21. Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity.
Antolino-Lobo I; Meulenbelt J; Nijmeijer SM; Scherpenisse P; van den Berg M; van Duursen MB
Drug Metab Dispos; 2010 Jul; 38(7):1105-12. PubMed ID: 20388857
[TBL] [Abstract][Full Text] [Related]
22. Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate.
Sun C; Zhao H; Li W; Jia Y; Yang Y; Peng Y; Zheng J
Drug Metab Dispos; 2021 Oct; 49(10):892-901. PubMed ID: 34312304
[TBL] [Abstract][Full Text] [Related]
23. Metabolomic screening and identification of the bioactivation pathways of ritonavir.
Li F; Lu J; Ma X
Chem Res Toxicol; 2011 Dec; 24(12):2109-14. PubMed ID: 22040299
[TBL] [Abstract][Full Text] [Related]
24. Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant.
Bergström MA; Isin EM; Castagnoli N; Milne CE
Drug Metab Dispos; 2011 Oct; 39(10):1823-32. PubMed ID: 21733882
[TBL] [Abstract][Full Text] [Related]
25. Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions
Paludetto MN; Stigliani JL; Robert A; Bernardes-Génisson V; Chatelut E; Puisset F; Arellano C
Chem Res Toxicol; 2020 Jan; 33(1):181-190. PubMed ID: 31535851
[TBL] [Abstract][Full Text] [Related]
26. Metabolic activation of the indoloquinazoline alkaloids evodiamine and rutaecarpine by human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.
Wen B; Roongta V; Liu L; Moore DJ
Drug Metab Dispos; 2014 Jun; 42(6):1044-54. PubMed ID: 24696463
[TBL] [Abstract][Full Text] [Related]
27. CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction.
Zamperini C; Dreassi E; Vignaroli G; Radi M; Dragoni S; Schenone S; Musumeci F; Valoti M; Antiochia R; Botta M
Drug Metab Pharmacokinet; 2014; 29(6):433-40. PubMed ID: 24850316
[TBL] [Abstract][Full Text] [Related]
28. The roles of CYP3A and CYP2B isoforms in hepatic bioactivation and detoxification of the pyrrolizidine alkaloid senecionine in sheep and hamsters.
Huan JY; Miranda CL; Buhler DR; Cheeke PR
Toxicol Appl Pharmacol; 1998 Aug; 151(2):229-35. PubMed ID: 9707499
[TBL] [Abstract][Full Text] [Related]
29. Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A(2A)/A(1) antagonist by minimizing bioactivation to an iminium ion reactive intermediate.
Lim HK; Chen J; Sensenhauser C; Cook K; Preston R; Thomas T; Shook B; Jackson PF; Rassnick S; Rhodes K; Gopaul V; Salter R; Silva J; Evans DC
Chem Res Toxicol; 2011 Jul; 24(7):1012-30. PubMed ID: 21667953
[TBL] [Abstract][Full Text] [Related]
30. Metabolite characterization of anti-cancer agent gefitinib in human hepatocytes.
Surve P; Ravindran S; Acharjee A; Rastogi H; Basu S; Honrao P
Drug Metab Lett; 2014 Jul; 7(2):126-36. PubMed ID: 24628403
[TBL] [Abstract][Full Text] [Related]
31. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
32. Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction.
Zhang T; Zhang K; Ma L; Li Z; Wang J; Zhang Y; Lu C; Zhu M; Zhuang X
J Pharm Sci; 2018 Apr; 107(4):979-983. PubMed ID: 29247736
[TBL] [Abstract][Full Text] [Related]
33. Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation.
Indra R; Pompach P; Martínek V; Takácsová P; Vavrová K; Heger Z; Adam V; Eckschlager T; Kopečková K; Arlt VM; Stiborová M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295928
[TBL] [Abstract][Full Text] [Related]
34. Identification of amino acid and glutathione N-conjugates of toosendanin: bioactivation of the furan ring mediated by CYP3A4.
Yu J; Deng P; Zhong D; Chen X
Chem Res Toxicol; 2014 Sep; 27(9):1598-609. PubMed ID: 25105339
[TBL] [Abstract][Full Text] [Related]
35. A novel biotransformation of alkyl aminopyrrolidine to aminopiperidine ring by human CYP3A.
Chen Y; Skiles GL; Shou M; Hickman D; Hsieh F
Drug Metab Dispos; 2011 Sep; 39(9):1668-73. PubMed ID: 21673127
[TBL] [Abstract][Full Text] [Related]
36. Characterization of phase I metabolism of resibufogenin and evaluation of the metabolic effects on its antitumor activity and toxicity.
Ning J; Yu ZL; Hu LH; Wang C; Huo XK; Deng S; Hou J; Wu JJ; Ge GB; Ma XC; Yang L
Drug Metab Dispos; 2015 Mar; 43(3):299-308. PubMed ID: 25504504
[TBL] [Abstract][Full Text] [Related]
37. Species-specific Bioactivation of Morpholines as a Causative of Drug Induced Liver Injury Observed in Monkeys.
Gunduz M; Argikar UA; Cirello AL; Brown AP; Bonazzi S; Walles M
Drug Metab Bioanal Lett; 2023 Dec; ():. PubMed ID: 38047363
[TBL] [Abstract][Full Text] [Related]
38. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Teng WC; Oh JW; New LS; Wahlin MD; Nelson SD; Ho HK; Chan EC
Mol Pharmacol; 2010 Oct; 78(4):693-703. PubMed ID: 20624855
[TBL] [Abstract][Full Text] [Related]
39. Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics.
Zhou ZM; Wang YK; Yan DM; Fang JH; Xiao XR; Zhang T; Cheng Y; Xu KP; Li F
J Pharm Biomed Anal; 2020 Feb; 180():113045. PubMed ID: 31887668
[TBL] [Abstract][Full Text] [Related]
40. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.
Ho HK; Chan JC; Hardy KD; Chan EC
Drug Metab Rev; 2015 Feb; 47(1):21-8. PubMed ID: 25639891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
